• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
KNSA

KNSA

Kiniksa Pharmaceuticals, Ltd.

NASDAQHealthcareBiotechnologyBM

USD47.85

+0.93 (+1.98%)

Rating:B

Company Profile

CEO

Sanj K. Patel

IPO Date

2018-05-25

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

BM

Market Metrics

Open

$47.41

Prev. Close

$46.92

Day Low

$47.41

Day High

$48.44

52W Low

$26.27

52W High

$59.87

Market Cap

$3.60B

Volume

0.49M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

38.8%

Avg Negative

1.5%

Avg Neutral

59.8%

News Feed

Kiniksa Pharmaceuticals to Report Second Quarter 2021 Financial Results on August 3, 2021

GlobeNewsWire·7/20/2021·↑ positive

Kiniksa Announces Issuance of U.S. Patent for Treatment of Recurrent Pericarditis

GlobeNewsWire·6/8/2021·↑ positive

Kiniksa Outlines Next Steps for the Development of Mavrilimumab

GlobeNewsWire·6/8/2021
·↑ positive

Kiniksa Pharmaceuticals to Present at Goldman Sachs 42nd Annual Global Healthcare Conference

GlobeNewsWire·6/1/2021·↑ positive

Kiniksa: A Look At Mavrilimumab

Seeking Alpha·5/3/2021·↑ positive

Kiniksa Announces Commercial Availability of ARCALYST ® (rilonacept) for Recurrent Pericarditis

GlobeNewsWire·4/1/2021·↑ positive

Kiniksa Announces FDA Approval of ARCALYST ® (rilonacept) for Recurrent Pericarditis

GlobeNewsWire·3/18/2021·↑ positive

Kiniksa Reports Fourth Quarter and Full-Year 2020 Financial Results and Corporate and Pipeline Activity

GlobeNewsWire·2/23/2021·↑ positive

Kiniksa Pharmaceuticals to Present at 39th Annual J.P. Morgan Healthcare Conference

GlobeNewsWire·1/4/2021·↑ positive

Kiniksa Announces Data from U.S. Investigator-Initiated Study of Mavrilimumab in Severe COVID-19 Pneumonia and Hyperinflammation

GlobeNewsWire·12/22/2020·↑ positive